Two Peptides, One Skin Question

The short version

Rejuvenation Peptide is a reading desk, not a store. It collects what the published research literature actually says about two peptides that keep appearing in conversations about skin remodeling, hair, and aesthetic tissue repair: GHK-Cu and the GLOW blend. A peptide is a short chain of amino acids — the same building blocks as proteins, only far smaller. GHK-Cu is a three-amino-acid copper-carrying molecule drawn from the structure of collagen itself; GLOW is a three-peptide co-formulation that adds two tissue-repair compounds (BPC-157 and TB-500) to that copper tripeptide.

This desk does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence actually reaches. GHK-Cu has small but real human topical data; the GLOW blend has no combination study at all — its rationale is entirely extrapolated from single-constituent work. None of these is an approved medicine. We do not sell anything, we do not give medical advice, and we never list a human dose.

What are research peptides?

Proteins in your body — collagen in skin, an enzyme in the gut, a signaling hormone — are long chains of amino acids folded into a functional shape. A peptide is a much shorter version of the same idea: sometimes only three or four amino acids long. Because they are small and specific, peptides can act as signals that fit particular receptors on the surface of cells, switching repair, synthesis, or anti-inflammatory programs on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, and occasionally in early human pilots — but has not been approved by a regulatory agency as a medicine. Suppliers describe these compounds as being for laboratory research use only, and that framing matters: dosing, long-term safety, and real-world human effectiveness are usually unestablished. When this desk reports a number, it reports it the way the original study did — for example, studied at 10^-9 M in human fibroblast cultures — never as a recommendation.

How these two fit into skin research

The two entries on this desk approach skin and tissue repair from different angles and at very different evidence levels.

GHK-Cu is the lead. It is a copper-binding tripeptide (glycine-histidine-lysine chelated to a Cu(II) ion) that occurs naturally within the structure of type I collagen. At picomolar-to-nanomolar concentrations it signals dermal fibroblasts to synthesize collagen, elastin and glycosaminoglycans, while rebalancing the enzymes that break matrix down ^[4][6]. In a 2025 review covering clinical trials and delivery science, topical GHK-Cu raised collagen production in 70% of treated subjects versus 50% for vitamin C and 40% for retinoic acid ^[1]. It also holds the most controlled human signal on this desk: a 6-month trial of 45 men found significant hair-count increases with a GHK-containing topical versus placebo ^[3].

GLOW is built on that GHK-Cu foundation but adds two tissue-repair peptides — BPC-157 (pro-angiogenic, studied primarily in animal models ^[10]) and TB-500 (an actin-binding fragment linked to cell migration) — to create a multi-peptide combination. A 2026 Sports Medicine narrative review names all three constituents among unapproved peptides with favorable animal-model signals but scarce human safety data ^[8]. The combination itself has never been tested in a controlled study.

Together they sketch the top two layers of the skin-repair story: the matrix-building signal (GHK-Cu) and the vascular-and-repair amplifier rationale that the GLOW blend represents. Use the directory to read each one, or compare these peptides side by side.

A note on how this desk reads the literature

Rejuvenation Peptide is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source. Where the evidence is thin, single-lab, or preclinical, we say so plainly — that is part of the record, not a footnote. We describe research findings and the cited cautions that come with them. We do not recommend, prescribe, or sell. The aim is a precise, numbers-forward map of what is known, so you can see where the data are solid and where a claim outpaces the evidence.